1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Press Releases
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société ASCELIA PHARMA AB (PUBL)
05/11QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals
AQ
05/10Ascelia Pharma's Food Effect Study shows that Orviglance image enhancement of the liver..
AQ
05/05Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022
AQ
04/11Ascelia Pharma publishes Annual Report for 2021
AQ
04/05Notice of annual general meeting in ascelia pharma ab
AQ
04/01CFO Kristian Borbos to leave Ascelia Pharma
AQ
03/31Number of shares and votes in Ascelia Pharma AB
AQ
03/31HC ANDERSEN CAPITAL : Release of new Ascelia Pharma investment case
AQ
03/22New independent market research says 84% US healthcare professionals likely to use Orvi..
AQ
03/11Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study
AQ
03/07Ascelia Pharma suspends clinical activities in Russia
AQ
03/02Issue and repurchase of series C shares for share saving program
AQ
02/15Results from Orviglance comparison study to gadolinium accepted for oral presentation a..
AQ
02/10QUARTERLY REPORT Q4 2021 : Strong data for Orviglance vs. a gadolinium contrast agent
AQ
2021Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
AQ
2021Results from Orviglance comparison study to gadolinium presented at RSNA 2021
AQ
2021Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
AQ
2021QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration
AQ
2021ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed
AQ
2021ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
2021QUARTERLY REPORT Q2 2021 : Preparing Oncoral for the next level
AQ
2021ASCELIA PHARMA : Covid-19 extends recruitment period of SPARKLE study
AQ
2021ASCELIA PHARMA : Abstract for Orviglance comparison study to gadolinium accepted at the wo..
AQ
2021ASCELIA PHARMA : receives conditional FDA acceptance for brand name Orviglance
AQ
2021QUARTERLY REPORT Q1 2021 : US office opened in preparation of launch
AQ
2021ASCELIA PHARMA : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 20..
AQ
2021ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA AB : publishes prospectus regarding admission to trading of newly issued sh..
AQ
2021ASCELIA PHARMA : Bulletin from the extraordinary general meeting in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA : Issue and repurchase of series C shares for share saving program
AQ
2021ASCELIA PHARMA : Notice of annual general meeting in ascelia pharma ab
AQ
2021ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA : publishes Annual Report for 2020
AQ
2021ASCELIA PHARMA : Notice of extraordinary general meeting in Ascelia Pharma
AQ
2021ASCELIA PHARMA : has carried out a directed new share issue raising SEK 200 million
AQ
2021ASCELIA PHARMA : intends to carry out a directed new share issue
AQ
2021ASCELIA PHARMA : opens US office in preparation for Mangoral launch
AQ
2021QUARTERLY REPORT Q4 2020 : Mangoral shows high diagnostic value in new study
AQ
2021ASCELIA PHARMA : Information regarding transfer of shares in Ascelia Pharma AB from CMC SP..
AQ
2021ASCELIA PHARMA : presents clinical development plan for Oncoral as a novel chemotherapy
AQ
2020ASCELIA PHARMA : gets US patent for second generation Mangoral
AQ
2020ASCELIA PHARMA : New study shows Mangoral's lesion visualization as effective as gadoliniu..
AQ
2020QUARTERLY REPORT Q3-2020 : Raised market estimate for Mangoral and preparing for market la..
AQ
2020ASCELIA PHARMA : EMA confirms Mangoral eligible for the centralized regulatory procedure i..
AQ
2020ASCELIA PHARMA : Upgraded estimate of addressable market for Mangoral to $500-600 million ..
AQ
2020ASCELIA PHARMA : Invitation to Ascelia Pharma's virtual Capital Markets Day
AQ
2020ASCELIA PHARMA : First commercial scale manufacturing of Mangoral
AQ
2020QUARTERLY REPORT Q2-2020 : First participant in the hepatic study
AQ
2020ASCELIA PHARMA PUBL : Change in number of shares and votes in Ascelia Pharma AB
AQ
2020ASCELIA PHARMA PUBL : completes a directed new share issue of 4,697,781 shares, raising ap..
AQ
2020VATOR SECURITIES : Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged.
AQ
2020ASCELIA PHARMA PUBL : Updated SPARKLE timelines due to Covid-19 impact
AQ
2020INTERIM FINANCIAL REPORT Q1-2020 : First patient enrolled in Phase 3 study SPARKLE
AQ
2020ASCELIA PHARMA PUBL : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 M..
AQ
2020ASCELIA PHARMA PUBL : First participant enrolled in the clinical hepatic impairment study ..
AQ
2020ASCELIA PHARMA PUBL : Patent for Oncoral approved in Japan
AQ
2020ASCELIA PHARMA PUBL : publishes Annual Report for the financial year 2019
AQ
2020ASCELIA PHARMA PUBL : Nomination Committee proposes election of Lauren Barnes to the Board..
AQ
2020ASCELIA PHARMA PUBL : Correction to press release regarding in change in number of shares ..
AQ
2020ASCELIA PHARMA PUBL : Change in number of shares and votes in Ascelia Pharma AB
AQ
2020ASCELIA PHARMA PUBL : Leading Ascelia Pharma through the Covid-19 period
AQ
2020ASCELIA PHARMA PUBL : Issue and repurchase of series C shares for share saving program
AQ
2020VATOR SECURITIES : Ascelia Pharma: A rocket roll out is the key to success
AQ
2020ASCELIA PHARMA PUBL : First patient enrolled in pivotal Phase III clinical study SPARKLE w..
AQ
20202019 YEAR-END FINANCIAL REPORT : Sites opened for recruitment to the pivotal Phase III stu..
AQ
2020ASCELIA PHARMA PUBL : Five sites now opened in the pivotal Phase III clinical study SPARKL..
AQ
2019ASCELIA PHARMA PUBL : Nomination Committee appointed for AGM 2020 in Ascelia Pharma AB
AQ
2019ASCELIA PHARMA PUBL : appoints Julie Waras Brogren as Chief Commercial Officer
AQ